Adiponectin levels showed a trend of improvement in the enavogliflozin group, with a greater increase than in the placebo group; however, this difference was not statistically significant.
← all excerpts
Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.
1
—
—